Healthcare / Medical Instruments & SuppliesKuala Lumpur
$1.26
+0.06 (+5.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $37.8M · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
56/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.2B
P/E
21.0x
↑EV/EBITDA
8.5x
↓ROE
4.1%
↑Gross Margin
44.5%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-9.3%
FCF CAGR
—
FCF margin
2.2%
FCF / Net income
0.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.75B · net income $152.8M · FCF $37.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.75B | $1.75B | $1.92B | $1.59B | $2.34B |
| Net Income | $152.8M | $152.8M | $118.3M | $13.3M | $157.1M |
| EBITDA | $272.4M | $272.4M | $266.8M | $149.2M | $348.2M |
| EPS | 0.06 | 0.06 | 0.05 | 0.01 | 0.06 |
| Gross Margin | 44.5% | 44.5% | 40.6% | 40.3% | 40.6% |
| Operating Margin | 7.9% | 7.9% | 6.0% | 1.8% | 7.9% |
| Net Margin | 8.7% | 8.7% | 6.2% | 0.8% | 6.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.00 | 0.02 |
| Current Ratio | 9.35 | 9.35 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $37.8M | $37.8M | $-177.5M | $115.6M | $-22.0M |
| Returns | |||||
| ROE | 4.1% | 4.1% | 3.2% | 0.3% | 4.1% |
| Valuation | |||||
| P/E | 21.00 | 21.00 | 59.91 | 378.85 | 17.53 |
| EV/EBITDA | 8.49 | 8.49 | 23.22 | 25.28 | 4.28 |
| P/B | 0.86 | 0.86 | 1.95 | 1.31 | 0.71 |
| Growth & Yield | |||||
| Revenue Growth | -8.7% | -8.7% | 20.4% | -32.1% | — |
| EPS Growth | 29.7% | 29.7% | 792.3% | -91.6% | — |
| Dividend Yield | 3.2% | 3.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
22.9%
EPS terminal req.
$0.11
Spread vs growth
6.8%
5Y implied EPS CAGR
17.6%
EPS terminal req.
$0.14
Spread vs growth
12.2%
10Y implied EPS CAGR
13.7%
EPS terminal req.
$0.22
Spread vs growth
16.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-20.5%
Start / end P/E
35.6x → 20.9x
EPS bridge
0.05 → 0.06
Residual
-12.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.